17,261 trials
Arterial Stiffness · Vitamin K2 Deficiency
Primary: Reduction From Baseline in Carotid-femoral Pulse Wave Velocity at 8 Weeks — -1.4 m/s
Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia · Stage I Small Lymphocytic Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Vorinostat That Can be Combined With Fludarabine Phosphate, Cyclophosphamide and Rituximab (FCR) (Phase I) — 400; 400 mg
Iron Deficiency Anemia
Primary: Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane) — -11.90; -1.06; -12.37; -11.14 mg
Idiopathic Scoliosis
Primary: Intra- and Post-operative Pain Relief — 0.34; 0.26; 0.38 mg/kg
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 4; 4; 4; 0 Participants
Depression
Primary: Change in Montgomery and Asberg Depression Rating Scale (MADRS) — 3.20; 5.77; 4.83 units on a scale
Healthy
Primary: Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following G-CSF Administration — 16 unique cytokine genes affected
Chronic Obstructive Pulmonary Disease - COPD
Primary: Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Over the 12 h Period Immediately After Morning Study Drug…
Chronic Hepatitis C
Primary: Percentage of Subjects With Sustained Virologic Response (SVR12) 12 Weeks Post-treatment — 66 Participants
Mucosal Melanoma · Recurrent Melanoma · Recurrent Uveal Melanoma
Primary: Changes in the Concentration and Number of CD8+ Cells Infiltrating Tumor by IHC by Normalization of Kyn/Trp Ratios. — 0.5; 4.0 Ratio: Day21CD8s/Day0CD8s
Osteoarthritis of the Knee
Primary: To Evaluate the Efficacy of X0002 Spray Compared to Placebo for Relief of Knee Pain in Subjects With Osteoarthritis (OA) of the Knee
Sickle Cell Anemia
Primary: Number of Participants With a Reduction in Invariant Natural-Killer T-Cell (iNKT Cell) Activation by 70% or More — 21; 10 Participants
Onychomycosis
Primary: The Percentage of Participants Who Achieve Effective Treatment at Week 52 — 54; 38; 29; 21 Percentage of participants — p=<0.001
Alcohol Drinking
Primary: Number of Drinks Consumed — 2.1; 2.05; 1.5; 1.7 number of drinks
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Confirmed Overall Response Rate (Stringent Complete Response [sCR], Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR]) With Single…